当全球医药产业仍在“专利悬崖”与“支付方压价”双重阴影下踯躅,强生(Johnson & Johnson)用一份超预期的2025Q2财报,给出了截然不同的信号:营收稳步抬升、盈利健康扩张、全年指引再度上调。这家横跨 MedTech (医疗科技)与 Innovative Medicine(创新制药) 两大领域的巨舰,正在用“双引擎”证明自己不仅能穿越周期,还能在周期中加速。双引擎驱动,业绩亮眼强生公司...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.